Targeted Therapy in Systemic Sclerosis

Murray Baron, M.D.*

Chief Division of Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; and Professor of Medicine, McGill University, Montreal, Quebec, Canada

ABSTRACT

Targeted therapies use an understanding of the pathophysiology of a disease in an individual patient. Although targeted therapy for systemic sclerosis (SSc, scleroderma) has not yet reached the level of patient-specific treatments, recent developments in the understanding of the global pathophysiology of the disease have led to new treatments based on the cells and pathways that have been shown to be involved in the disease pathogenesis. The presence of a B cell signature in skin biopsies has led to the trial of rituximab, an anti-CD20 antibody, in SSc. The well-known properties of transforming growth factor (TGF)-β in promoting collagen synthesis and secretion has led to a small trial of resolimumab, a human IgG4 monoclonal antibody capable of neutralizing TGF-β. Evidence supporting important roles for interleukin-6 in the pathogenesis of SSc have led to a large trial of tocilizumab in SSc. Soluble guanylate cyclase (sGC) is an enzyme that catalyzes the production of cyclic guanosine monophosphate (cGMP) upon binding of nitric oxide (NO) to the sGC molecule. Processes such as cell growth and proliferation are regulated by cGMP. Evidence that sGC may play a role in SSc has led to a trial of riociguat, a molecule that sensitizes sGC to endogenous NO. Tyrosine kinases (TKs) are involved in a wide variety of physiologic and pathological processes including vascular remodeling and fibrogenesis such as occurs in SSc. This has led to a trial of nintedanib, a next-generation tyrosine-kinase (TK) inhibitor which targets multiple TKs, in SSc.

KEY WORDS: Drug treatment, scleroderma, systemic sclerosis, targeted, therapy

Abbreviations: ALK, anaplastic lymphoma kinase; cGMP, cyclic guanosine monophosphate; COMP, cartilage oligomeric protein; dSSc, diffuse cutaneous systemic sclerosis; EGFR, epidermal growth factor receptor; FVC, forced vital capacity; G-kinases, protein kinases; GMP, guanosine monophosphate; IL-6, interleukin-6; ILD, interstitial lung disease; lcSSc, limited cutaneous systemic sclerosis; MRSS, modified Rodnan skin score; NO, nitric oxide; PDEs, phosphodiesterases; RTX, rituximab; sGC, soluble guanylate cyclase; SSc, systemic sclerosis, scleroderma; TGF-β, transforming growth factor beta; THBS1, thrombospondin-1; TK, tyrosine kinase.

Citation: Baron M. Targeted Therapy in Systemic Sclerosis. Rambam Maimonides Med J 2016;7 (4):e0030.
doi:10.5041/RMMJ.10257

Review

Copyright © 2016 Baron. This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conflict of interest: No potential conflict of interest relevant to this article was reported.

*E-mail: mbaron@ruh.jgh.mcgill.ca
INTRODUCTION

Systemic sclerosis (SSc, or scleroderma) is a serious multi-system disorder of connective tissue disease characterized clinically by thickening and fibrosis of the skin and involvement of internal organs, most commonly the lungs, gastrointestinal tract, and heart. Systemic sclerosis affects predominantly women in the prime of their life and is associated with increased morbidity and mortality. Systemic sclerosis is a rare disease with prevalence estimates varying from 30 to 443/million population.1,2

Because the disease is so heterogeneous and rare, it has been difficult to perform high-quality randomized controlled clinical trials. Unfortunately, the few such trials performed, especially early ones, have not been uniformly successful. Therapies studied in randomized controlled trials that have failed include ketanserin,3 15-fluorouracil,4 ketotifen,5 interferon-gamma,6 interferon-alpha,7 penicillamine,8 relaxin,9-11 methotrexate,11 oral collagen,12 imatinib,13-14 IVIG,15 macitentan,16 and bosentan.17-18 More recently there have been some hopeful positive trials with statins,19 cyclophosphamide,20 and autologous stem cell transplantation.21,22

Could we be more successful with a more targeted approach to therapy in SSc, similar to that taken in other diseases such as cancer? For example, in melanoma, BRAF kinase-activating mutations can turn BRAF into an oncogene, and the presence of such mutations has led to specific therapy.23 Similar analyses of non-small cell lung cancer has found that mutations in the epidermal growth factor receptor (EGFR), translocations involving the anaplastic lymphoma kinase (ALK) tyrosine kinase, oncogenic RAS mutations, and other driver mutations, such as BRAF, can be treated with therapy targeted at these abnormalities.24

In SSc we are entering a very exciting and hopeful era with 316 trials for SSc listed on ClinicalTrials.gov.25 Some of these trials have used, or are using, new biologic agents or kinase inhibitors such as abatacept,26 rituximab,27 imatinib, dasatinib, fasudil,27 nintedanib,28 and fresolimumab, an anti-transforming growth factor (TGF) antibody.29 A phase III trial of tocilizumab is underway. Some of these trials are based on the concept of targeting specific pathophysiologic abnormalities that have been found in SSc. We have thus hopefully moved away from general immunosuppressives such as cyclophosphamide or methotrexate to drugs that inhibit specific pathways or cells thought to be active in SSc. These represent the first steps toward personalized targeted medicine in SSc.

RITUXIMAB

One promising approach to possible biomarkers that may indicate that a certain subset may respond to specific targeted therapy has come from the study of the gene expression found in skin biopsies.29–37 Early work demonstrated that some patients with SSc had a skin gene expression signature consistent with the presence of active B cells.30 This observation has led directly to two trials of rituximab (RTX), an anti-CD20 monoclonal antibody, in SSc.38,39 In the first publication 15 patients with diffuse cutaneous systemic sclerosis (dcSSc) received two doses of rituximab 1 g each, 2 weeks apart.39 The mean change in the modified Rodnan skin score (MRSS) between baseline and 6 months was not significant. Results of pulmonary function tests and other measures of major organ involvement were stable. The modest B cell infiltrates that were present in most skin biopsy specimens at baseline were completely depleted at 6 months in most patients. In the other trial, 14 patients with SSc were evaluated.38 Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks, whereas six patients (control group) received standard treatment alone. There was a significant increase of forced vital capacity (FVC) in the RTX group compared with baseline. The median percentage of improvement of FVC in the RTX group was 10.25%, whereas that of deterioration in the controls was 5.04% (P=0.002). Skin thickening, assessed with the MRSS, improved significantly in the RTX group compared with the baseline score (mean±SD 13.5±6.84 versus 8.37±6.45 at baseline versus 1 year, respectively, P<0.001). Rituximab depleted both circulating B cells and dermal B cells. In the RTX-treated group, there was a significant reduction of collagen deposition in the papillary dermis at 24 weeks compared with baseline which was not seen in the control group. The EUSTAR group also published an observational study assessing the effects of RTX on skin and lung fibrosis in patients with SSc.40 Comparison between RTX-treated patients and matched controls revealed a significant difference in favor of RTX. However, to this author’s knowledge, rituximab has not strictly been employed as targeted therapy such as treating only those patients with a skin biopsy showing B cell activation or analyzing the results in patients with skin biopsies that show B cell activation versus those with no such pattern.
FRESOLIMUMAB

It is well-known that TGF-β promotes collagen synthesis, secretion, processing, and cross-linking as well as secretion of other matrix molecules, such as fibronectin and thrombospondin. This has led to an interest in using anti-TGF-β in SSc. The first trial of CAT-192, a recombinant human antibody that neutralizes TGF-β1, was not successful. However, a more recent study tested fresolimumab, a first-in-class human IgG4κ monoclonal antibody capable of neutralizing all mammalian isoforms of TGF-β. There is a four-gene, pharmacodynamic biomarker of SSc skin disease, based on gene expression in a mid-forearm skin biopsy. Two of the four genes making up the biomarker, thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP), are highly regulated by TGF-β. In this open uncontrolled trial, the predefined primary efficacy outcome was change in COMP and THBS1 mRNA expression in skin after treatment compared with that at baseline. Subjects showed rapid declines in THBS1 and COMP gene expression in skin biopsies after treatment with fresolimumab. THBS1 and COMP gene expression was strikingly higher in SSc patient cohorts than in healthy control skin, and changes in gene expression in study patients generally correlated with changes in MRSS.

TOCILIZUMAB

Another promising therapy consists of inhibition of interleukin (IL)-6. Evidence supports important roles for IL-6 in the pathogenesis of SSc, e.g. dermal fibroblasts from SSc patients constitutively express higher levels of IL-6 than found in healthy controls; serum and skin levels of IL-6 are elevated in SSc patients with early disease and in patients with SSc or SSc-interstitial lung disease (ILD), and increased IL-6 levels have been associated with higher mortality, more severe skin involvement, and increased incidence of progressive pulmonary decline. Strategies to block the IL-6 response resulted in a significant reduction of procollagen type I in cultured SSc fibroblasts and myofibroblastic differentiation in dermal fibroblasts in a bleomycin-induced model of dermal sclerosis. Some indirect evidence of increased effect of IL-6 in SSc derives from the fact that CRP is elevated in SSc although not to levels associated with diseases such as rheumatoid arthritis. C-reactive protein (CRP) levels in dcSSc are higher than in limited cutaneous SSc (lcSSc).

These findings have led to a phase II trial of tocilizumab in early dcSSc. The primary end-point showed a treatment difference of −2.70 MRSS units in favor of tocilizumab at week 24 but did not quite reach statistical significance. Exploratory analysis of lung function showed that fewer patients in the tocilizumab arm had a decline in percentage-predicted forced vital capacity than in the placebo arm by comparison of the cumulative distribution by week 48. Tocilizumab specifically downregulated the expression of myeloid-associated genes in the skin and decreased circulating levels of CCL18, a chemokine associated with fibrosis and progression of SSc-associated lung disease. A phase III trial is underway.

RICIGUAT

Soluble guanylate cyclase (sGC) is an enzyme that catalyzes the production of cyclic guanosine monophosphate (cGMP) upon binding of nitric oxide (NO) to the sGC molecule. Once released by the sGC, cGMP can act as a second messenger to activate further downstream targets, such as cGMP-regulated ion channels, protein kinases (G-kinases), phosphodiesterases (PDEs). Through those effectors, cGMP regulates a variety of physiological processes, including cell growth and proliferation, vascular tone and remodeling, immune responses, and neuronal transmission. Riociguat is a molecule that sensitizes sGC to endogenous NO by stabilizing NO–sGC binding. Riociguat also directly stimulates sGC, independent of NO, resulting in increased generation of cGMP. Riociguat has been shown in large randomized controlled clinical trials to be effective in patients with different forms of pulmonary hypertension including patients with SSc-related pulmonary arterial hypertension (PAH).

There is evidence that sGC may play a role in SSc. Soluble guanylate cyclase activators inhibited the release of TGF-β-induced extracellular matrix proteins from primary dermal fibroblasts obtained from both normal volunteers and SSc subjects, and dermal fibroblast was reduced in the bleomycin skin fibrosis model of SSc. Riociguat has been shown in large randomized controlled clinical trials to be effective in patients with different forms of pulmonary hypertension, including patients with SSc-related PAH, and is now in a trial for the skin thickening of SSc.
NINTEDANIB

The last molecule that we will briefly address is nintedanib, a next-generation, potent, indolinone-derived small molecule tyrosine-kinase (TK) inhibitor which targets multiple TKs. Tyrosine kinases are involved in a wide variety of physiologic and pathological processes including vascular remodeling and fibrogenesis. Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDGFR-α and PDGFR-β, FGFR-1, FGFR-2, FGFR-3, VEGFR-1, VEGFR-2, VEGFR-3, and Src.

Nintedanib reduced differentiation of myofibroblasts and the release of collagen of dermal fibroblasts from patients with SSc and healthy individuals. Nintedanib also showed anti-fibrotic effects in a dose-dependent manner in different animal models of SSc, including the bleomycin skin fibrosis model both in preventive and therapeutic applications, the chronic graft-versus-host disease model, and the Tsk-1 model. Interestingly, in the Fra-2 tg mouse model, nintedanib did not only inhibit skin and lung fibrosis but also improved the pulmonary vascular lesions resembling PAH. Based on these results, a large, randomized, placebo-controlled trial with nintedanib is currently initiated in patients with SSc for pulmonary fibrosis.

CONCLUSION

Although we are in an exciting new era of drug trials for SSc, and although the drugs discussed here are being used because of their abilities to interfere with specific cells or pathways that have been found to be involved in SSc or SSc models, the field of targeted therapy has not yet progressed quite as far as it has in cancer. The next big step will be to understand if the new drugs are effective specifically in patients who demonstrate abnormalities of the cells or pathways that are inhibited or activated by these new medications. Then we will be closer to developing a truly personalized approach to the treatment of this serious disease.

REFERENCES

1. Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 2009;61:400–4. Full Text
2. Chiffilot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37:223–35. Full Text
3. Ortonne JP, Toruzzi C, Dujardin P, Fraitag B. Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial. Br J Dermatol 1989;120:261–6. Full Text
4. Casas JA, Saway PA, Villarreal I, et al. 5-fluorouracil in the treatment of scleroderma: a randomised, double-blind, placebo controlled international collaborative study. Ann Rheum Dis 1990;49:926–8. Full Text
5. Gruber BL, Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991;34:362–6. Full Text
6. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996;23:654–8.
7. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299–305. Full Text
8. Clements PJ, Seibold J, Furst DE, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004;33:249–63. Full Text
9. Seibold J, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871–9. Full Text
10. Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:1102–11. Full Text
11. Pope JE, Bellamy N, Seibold J, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–8. Full Text
12. Postlethwaite AE, Wong WK, Clements P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008;58:1810–22. Full Text
13. Pope J, McBain D, Petrich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011;63:3547–51. Full Text
14. Prey S, Ezzedine K, Doussau A, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012;167:138–44. Full Text
15. Takehara K, Ihn H, Sato S, et al. A randomized, double-blind, placebo-controlled trial: ivavenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013;31:151–6.
16. Khanna D, Denton CP, Merkel PA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 2016;315:1975–88. Full Text
17. Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101–8. Full Text
18. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–93. Full Text
19. Abou-Ray A, Abou-Ray S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008;35:1801–8.
20. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in systemic sclerosis lung disease. N Engl J Med 2006;354:2655–66. Full Text
21. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498–506. Full Text
22. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490–8. Full Text
23. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80:561–7. Full Text
24. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38–47. Full Text
25. Clinical Trials Gov. 2016. Systemic sclerosis. Available at: http://bit.ly/2eQnXdi.
26. Clinical Trials Gov. Abatacept Scleroderma. 2016. Available at: http://bit.ly/2eXXGeI.
27. Clinical Trials Gov. Scleroderma Rituximab Trials. 2016. Available at: http://bit.ly/2c98lO.
28. Minier T, Pentek M, Brodzsky V, et al. Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 2010;49:1920–8. Full Text
29. Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015;122:795–807. Full Text
30. Chakravarty EF, Martyanov V, Fiorentino D, et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther 2015;17:159. Full Text
31. Whitfield ML, Finlay DI, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319–24. Full Text
32. Pendergrass SA, Whitfield ML, Gardner H. Understanding systemic sclerosis through gene expression profiling. Curr Opin Rheumatol 2007;19:561–7. Full Text
33. Sargent JL, Milano A, Connolly MK, Whitfield ML. Scleroderma gene expression and pathway signatures. Curr Rheumatol Rep 2008;10:205–11. Full Text
34. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008;3:e22696. Full Text
35. Chung I, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009;60:384–91. Full Text
36. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010;130:694–705. Full Text
37. Sargent J, Milano A, Bhattacharyya S, et al. A transforming growth factor-β (TGFβ)-responsive gene signature predicts more severe skin disease and occurrence of interstitial lung disease (ILD) in diffuse cutaneous systemic sclerosis (dcSSc) [Poster]. Nov 6–11, 2007 Annual Scientific Meeting of the American College of Rheumatology; Boston, MA. Available at: http://bit.ly/2eI1Gc (accessed August 24, 2016).
38. Daoussis D, Liossis SN, Tzamandas AC, et al. Experience with rituximab in scleroderma: results
39. Lafayatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:78–83. Full Text

40. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015;74:1188–94. Full Text

41. Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 2009;1:226–35. Full Text

42. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323–33. Full Text

43. O'Reilly S, Ciechomska M, Cant R, Hugle T, van Laar JM. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012;23:99–107. Full Text

44. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 over-expression in systemic sclerosis. Ann Rheum Dis 2012;71:1235–42. Full Text

45. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25:296–301. Full Text

46. Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveolar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009;11:R11. Full Text

47. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67–72. Full Text

48. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308–13. Full Text

49. Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012;180:65–76. Full Text

50. Desai R, Aouad J, Frechet M, et al. Targeting IL6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014;16:R157. Full Text

51. Muangchan C, Harding S, Kimdias S, Bonner A, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012;64:1465–14. Full Text

52. Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013;65:1375–80. Full Text

53. Khanna D, Denton CP, Jaheis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630–40. Full Text

54. Belik J. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr Opin Investig Drugs 2009;10:971–9.

55. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009;4:853–65. Full Text

56. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019–26. Full Text

57. Dees C, Beyer C, Distler A, et al. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis 2015;74:1621–5. Full Text

58. Hambly N, Granton J. Riociguat for the treatment of pulmonary hypertension. Expert Rev Respir Med 2015;9:679–9. Full Text

59. Antoniou SA, Kolb MR. Nintedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. iDRugs 2010;13:332–45.

60. Roth GJ, Binder R, Colbatszy F, et al. Nintedanib: from discovery to the clinic. J Med Chem 2015;58:1053–63. Full Text

61. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434–45. Full Text